Data compiled by Redley Lamar · ChainSifter Intelligence
3Suppliers
5Customers
3Debt Items
20Related Chains
Source-Backed Evidence Depth
Skye Bioscience, Inc. (SKYE) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
12Total relationships
3Distinct source URLs
6High confidence
0.788Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Skye Bioscience, Inc. Suppliers
Ticker
Name
Confidence
Evidence
HALOZYME-INC
HALOZYME-INC
92%
Halozyme will also be the Company's exclusive supplier of clinical and commercial supplies of the API for Halozyme's rHuPH20 bulk drug product.
LOHMAN-ASSOCIATES-INC
LOHMAN-ASSOCIATES-INC
92%
In connection with the appointment of Mr. Sharp, on March 31, 2026, the Company entered into a Master Services Agreement (the “Master Services Agreement”)with L&A, pursuant to which L&A agreed to pro…
Reciprocal relationship from BRGX graph: health utilizing the latest in technologies and top of class products in the health and wellness sector. He has served in that role since October 2012 to pres…
Reciprocal relationship from SPRC graph: pose regulatory sanctions including, among other things, refusal to approve a pending application for a new drug product, withdrawal of an approval or suspens…
MFDI-LLC
MFDI-LLC
62%
nts to Placement Agent 27.50 0.74 21,778 August 2023 Convertible Note Common Stock Warrants 5.16 7.63 340,000 August 2023 PIPE Financing Common Stock Warrants 5.16 7.63 2,325,537 January 2024 Pre-Fun…
OPERATIONS-SKYE-BIOSCIENCE-INC
OPERATIONS-SKYE-BIOSCIENCE-INC
62%
ses under employee stock purchase plan 18,461 18 29,553 — 29,571 Exercise of pre-funded warrants 2,374,494 2,375 ( 2,375 ) — — Net loss for the year ended December 31, 2025 — — — ( 55,924,814 ) ( 55,…
PINK-SHEETS-LLC
PINK-SHEETS-LLC
62%
ion or if we cannot otherwise maintain the confidentiality of our proprietary technology and other confidential information, then our ability to obtain patent protection or to protect our trade secre…
Skye Bioscience, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
SKYE-DEBT
Debt stack $116,700
90%
Market cache reports total debt of $116,700.
SKYE-DEBT-12562
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2025-12-31.
SKYE-DEBT-12561
Warrants outstanding: 100000
90%
xbrl warrant detail from xbrl 2024-12-31.
Skye Bioscience, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Skye Bioscience, Inc..
Skye Bioscience, Inc. Ownership
Holder
Name
Confidence
Evidence
SKYE-OWNER-5AM-VENTURE-MANAGEMENT-LLC
5AM Venture Management, LLC
90%
13F overlay lists 5AM Venture Management, LLC as top holder; 41 tracked holders.
Skye Bioscience, Inc. Extended Supply Chain Network
